Background. The design of diagnostic and preventive strategies have been prevented by gaps in knowledge of the epidemiology of congenital cytomegalovirus (cCMV) with the type of maternal infection as well as the lack of large-scale neonatal screening tools.
Congenital CMV (cCMV) is the main cause of neurological handicap of infectious origin with a birth prevalence of 0.65% worldwide [1] . Although cCMV meets most criteria for screening programs, none have been implemented in any country. This is explained by gaps in knowledge on several fronts. A better understanding of the epidemiology of cCMV related to both maternal primary and nonprimary infection is needed to evaluate the impact of universal maternal serological screening. A better knowledge of the performance of broad screening tools is mandated before considering universal neonatal screening.
Large scale screening studies have been published, but none has reported birth prevalence in the light of sociodemographics, obstetrical and serological data within the same population [2] [3] [4] [5] [6] [7] . We undertook universal screening of cCMV infection in live-born infants delivered in 2 French maternities located in the Paris area between September 2013 and August 2015. Screening was performed by CMV DNA detection and quantification by real-time polymerase chain reaction (PCR) in saliva [5, 7] . All positive screening tests were controlled in repeat samples allowing calculation of the positive predictive value of the screening test in saliva. For each infected newborn, the type of maternal infection was characterized between primary or nonprimary. Maternal demographics have rarely been considered and never accordingly to the type of maternal infection within the same study population [8] [9] [10] . We found that the type of maternal infection is closely related to sociodemographic characteristics with implications for prevention programs to be based upon.
MATERIALS AND METHODS

Population
Consecutive newborns were swabbed for saliva in 2 maternities in Paris (Necker and Poissy) between September 2013 and August 2015. Data were collected prospectively: maternal age, parity, gravidity, multiple pregnancies, employment status and socio professional categories, geographic origin, and gestational age at delivery.
Poissy-Saint Germain Hospital ethics committee approved the study (2013-A00213-42). Written informed consent was obtained before inclusion.
The study is registered in clinicaltrial.gov website under NCT01923636.
METHODS
Cytomegalovirus DNA Detection and Quantification in Newborn Saliva Samples
Saliva samples were collected at delivery with an open-celled foam bud swab for optimum absorption and release, combined with viral transport medium (Sigma-Virocult® M40 Compliant, MWE Medical Wire, Witshire, UK). PCR were run daily from Monday to Friday, samples were stored at +4°C before PCR for at most 4 days. CMV DNA was extracted from 200 µL of transport medium on the MagNaPure LC (Roche Diagnostic, Meylan, France). CMV DNA in saliva was amplified with an in-house assay [11] . To check for the quality of saliva samples, extraction and amplification, CMV PCR was duplexed with an in-house glyceraldehyde 3-phosphate dehydrogenase (GAPDH) PCR [12] . The 95% limit of detection of this assay was calculated (Appendix 1). CMV DNA was quantified in positive samples with CMV R-gene® kit (Argene, BioMérieux, Marcy l'Etoile, France). The linearity of CMV DNA quantification in saliva was tested (Appendix 2).
A second saliva sample and a blood sample were systematically collected 1-3 days later from all newborns with a first positive saliva sample.
Cytomegalovirus Serology in Pregnant Women
At Necker hospital, CMV serology testing is offered to all pregnant women at 11-14 weeks. Immunoglobuin G (IgG) and immunoglobulin (IgM) are tested on Liaison XL platform (DiaSorin, Antony, France). In case of positive IgM, IgG avidity is measured with the LIAISON® CMV IgG Avidity kit to exclude or confirm primary infection in pregnancy as already described [13] . Therefore, part of the mothers of screened newborns had CMV serology testing prospectively. Alternatively, maternal serology results for infected newborns were obtained retrospectively on stored sera. In France, serum samples are collected at first and third trimesters of pregnancy for serology testing and women seronegative for toxoplasmosis are tested monthly; all sera are stored for 1 year.
Definition of a Symptomatic/Asymptomatic Status at Birth
Symptomatic or asymptomatic status at birth relied on a combination of clinical, laboratory, audiometric (automated auditory brainstem response) and cerebral imaging assessments as described [14] (Appendix 3).
Statistical Analysis
Prevalence of cCMV was defined as the proportion of infected newborns among all live-born infants enrolled during the study period. The positive predictive value (PPV) of CMV PCR on saliva sample was defined as the proportion of patients with positive subsequent saliva control sample among those who were positive in the first saliva sample. Control samples were obtained only in cases with a positive PCR in the first saliva sample; the negative predictive value could therefore not be calculated.
Prevalence of cCMV and PVV of CMV PCR in saliva were estimated along with their 2-sided 95% Clopper-Pearson exact confidence intervals for binomial proportions. Descriptive analyses were presented as frequency with percentage, median with interquartile range, or mean with standard deviation. Between-groups comparisons were conducted using χ 2 test, Fisher exact test, or Student test as appropriate. Multinomial logistic regression was used to assess factors associated with neonatal infection following maternal non-primary or primary infection. Independent variables entered in the model showed P values < .05 on univariate analysis. Newborns screened from women referred with an already known CMV fetal infection were excluded from the prevalence calculation but unclouded to subsequent analysis. Risk ratio to deliver an infected baby for women seronegative before pregnancy and 95% confidence interval (CI) were estimated in a subgroup of women who had CMV serology done in the first trimester in Necker. To check for selection bias, sociodemographic and obstetrical data of mothers who delivered in Necker were compared between women who had a CMV serology done in the first trimester and those who had not. Analyses were performed using the R 3.13 software, R Core Team (2014; R: A language and environment for statistical computing, foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/).
RESULTS
Polymerase Chain Reaction Performance
The 95% limit detection of the in-house CMV/GAPDH duplex PCR assay was 869 (2.9 log 10 ) copies/mL ( Figure S1 ). The upper limit of quantification of CMV R-gene® PCR in saliva samples was 9.3 log 10 copies/mL ( Figure S2 ).
Prevalence of Cytomegalovirus Congenital Infection, Type of Maternal Infection and Neonatal Status (Figure 1)
The study was proposed to mothers of 11 857 liveborn neonates representing 84% of all births during the study period Members of staff were either too busy or forgot to propose the study to 2318 (16%) mothers. In sum, 76 newborns were not included because their mothers refused the study. And 41 saliva samples were defective (not labeled, broken vial…). Among the 11 740 newborns screened, 25 had a CMV PCR result not interpretable because of a negative GAPDH PCR suggesting improper sampling. In total, 11 715 neonates had an interpretable CMV PCR results, and 51 were screened and confirmed infected. Seven of these 51 newborns were excluded from the prevalence calculation because their mothers were referred with a known CMV fetal infection. The prevalence of cCMV was 0.37% (44/11 715) (95% CI: 0.246, 0.606) and was similar in Necker and Poissy: 0.39% (21/5296) (95% CI: 0.246, 0.606) and 0.36% (23/6419) (95% CI: 0.227, 0.537), respectively (P = .848). And 23 (52% 95% CI: 36.7, 67.6) and 21 (48%, 95% CI: 32.5, 63.3) cases followed maternal primary or nonprimary infection, respectively; similar proportions were found in Necker 57% (12/21) vs. 43% (9/21) and in Poissy 48% (11/23) vs. 52% (12/23) (P = .623).
Among the 44 infected neonates (51 minus 7 born from mothers referred for CMV infection), 9 (21%) were symptomatic including: 4 (9%) with hearing loss, 4 (9%) with isolated SGA (small for gestational age), and 1 with isolated thrombocytopenia. The proportions of neonates with symptoms and hearing loss were similar for both types of maternal infection in Necker and Poissy with 21% vs. 19% and 8.6% vs. 9.5%, respectively (P > .99). The 2 neonates infected after primary infection had profound unilateral hearing loss with threshold of 100 db in both cases. Whereas among the 2 neonates infected after nonprimary infection, one had moderate unilateral hearing loss (threshold 60 db), and the other had moderate to severe bilateral hearing loss with respective threshold of 60 db in the best ear and 70 db in the worst ear. (Table 1) The 48 mothers of the 51 infected neonates (44 plus the 7 infected newborns from referred mothers) were classified depending on the type of maternal infection. Retrospective CMV serology testing was performed in maternal stored sera for these 51 infected neonates. This allowed classification into primary and nonprimary group. Seroconversion during pregnancy was demonstrated in 16 women, the presence of positive IgG, positive IgM, and low or intermediate IgG avidity was evidenced in 12 women; these 28 women composed the primary All 3 groups were similar in age, gravidity, rate of multiple pregnancies, or gestational age at delivery. Mothers of infected newborns following primary infection were less often nulliparous than mothers of uninfected newborns (P = .01), but this was not true for mothers of newborns infected after nonprimary infection (P = .846). Mothers of newborns infected after primary infection were more often born in high-resource countries (P = .034). The opposite was true of mothers of newborns infected after nonprimary infection for whom country of birth was more often of low or intermediate resources (P = .03). There were more unemployed among mothers of newborns infected after nonprimary infection (P = .015), but this was not true of mothers of newborns infected after primary infection (P = .501). Mothers from the latter group belonged more often to socio professional groups with higher incomes than mothers of uninfected newborns (P = .019).
Maternal Risk Factors to Deliver an Infected Baby Following Maternal Primary or Nonprimary Infection (Table 2)
To be parous and to be born in a high-resource country were independent risk factors for delivering a baby infected after primary infection (odds ratio 
Risk of Delivering an Infected Newborn According to Maternal Cytomegalovirus Serology in the 1st Trimester (Figure 3)
Overall, 2378 women had a serology performed at 11-14 weeks in Necker laboratory and underwent neonatal screening, representing 45% of all women delivered in Necker. This subset was similar to the whole population of Necker in age, parity, gravidity, country of birth, and employment status (Appendix 4, Table  S1 ). It was therefore considered to be a representative subset of the population of women delivering in Necker.
Among these 2378 women, 1454 (61% 95% CI: 58, 62) were classified as seropositive before pregnancy based on serological profile in the first trimester (IgG positive/ IgM negative or IgG positive/IgM positive with high IgG avidity), and 924 (39%) were classified as seronegative before pregnancy (IgG negative/ IgM negative or IgG positive/IgM positive with low or intermediate IgG avidity). The risk to deliver an infected baby was significantly higher in seronegative women before pregnancy than in women seropositive before pregnancy (0.86% vs 0.2%, P = .021) (Figure 3 ).
DISCUSSION
We performed universal screening of all liveborn neonates in 2 maternities in France. The prevalence of cCMV was 0.37% in this population of Paris and greater Paris area, therefore within range of what was expected from the literature. Although worldwide birth prevalence of cCMV infection has been estimated to be 0.64% [15] , prevalence varies accordingly to the level of CMV immunity in pregnant women. Birth prevalence is higher (>1%) in low-resource countries where maternal seroprevalence is high (>95%) including most African and Asian countries [16] . These countries also have the lowest resources. However, in countries with intermediate maternal seroprevalence (around 55-60%), such as France [17, 18] the birth prevalence is expected to be around 0.4% [1] .
The proportions of congenital infections following primary and nonprimary maternal infections were 52% and 48%, respectively, for a 61% maternal seroprevalence. A search in PubMed including: "cytomegalovirus, " "congenital, " and "risk factors" did not retrieve a single previous prospective screening study linking maternal seroprevalence, birth prevalence of infection, and the respective role of primary and nonprimary infections within the same population. Because of this lack of combined data, models have been developed to predict the respective burden of cCMV arising from primary and nonprimary infections [19] [20] [21] . Applying these models to our population bearing a 61% seroprevalence leads to an expected proportion of congenital infections attributable to nonprimary infections of over 70% and not under 50% as observed [21] . In light of our data, these models seem therefore to be overestimating the proportion of congenital infections following nonprimary infections. Moreover, in our population, women seronegative before pregnancy had a 4-fold higher individual risk to deliver an infected baby than women seropositive before pregnancy.
In our study, the proportion of symptomatic infected neonates was higher than reported in a meta-analysis (20% vs 13%). This may be at least partly due to the definition of a symptomatic neonate that has evolved over time [15] . The proportion of neonates with hearing loss at birth was 10%, and this was similar in neonates infected after maternal primary or nonprimary infections. Neonatal hearing loss has long been thought to mainly Data are mean ± standard deviation, n (%), or n/N (%) where data are missing.
Countries of birth of mothers from the first group: France (87%), other European Countries (12%), North American countries (1%).
Countries of birth of mothers from the second group: North African countries (39%), non-North African countries (26%), East Asian countries (19%), Middle East countries (6%), South American countries (5%), others (5%).
Professional occupation: 1 = independent retailers, entrepreneurs, 2 = executives, intellectual professions, 3 = intermediate professions, 4 = employees, 5 = workers, 6 = unemployed. follow primary rather than nonprimary maternal infection [22] . However, our results together with other recent studies suggest that hearing loss related to maternal nonprimary infection is as severe as that related to maternal primary infection [4, 6, 23] . CMV detection in urine has been the gold standard for cCMV diagnosis for years. However, a recent large prospective study of cCMV screening showed that CMV PCR in saliva has excellent sensitivity and specificity compared to standard saliva rapid culture; and that saliva could therefore be used for cCMV screening [5] . Similar performance was reported between urine and saliva in 2 small studies [24, 25] . However, false positive cCMV diagnoses in saliva could be an issue because CMV is frequently present in breast milk [26] and in the birth canal [27] , and therefore contamination of the newborn's saliva samples could happen throughout the peripartum period. We systematically controlled positive results in repeat saliva and blood samples.
Among the 11 715 samples tested, 51 were true-positive and 36 were false-positive giving a PPV for cCMV screening in saliva samples of only 55%. CMV DNA quantification helped discriminate between false and true positive results since high viral loads (>4.0 log copies/mL) were only found in true positive samples. However, low viral loads were found both in true and false positive samples. Because the neonates were screened at birth in the delivery room, false positive samples could result from contamination by CMV DNA shed in vaginal secretions. These results indicate that a positive CMV PCR in saliva obtained from a neonate should be controlled in a subsequent sample particularly when the amount of CMV DNA detected is low.
Studies conducted in the United States reported higher birth prevalences of cCMV in African American women, younger than 25 years, with lower economic status, caring for preschool children and living in a household with more than 3 people [8] [9] [10] . Conversely, one study conducted in Australia reported an association between higher socioeconomic status and cCMV [28] . However, in these studies, sociodemographic characteristics of the women were not studied accordingly to the type of maternal infection. Our study provides a thorough analysis of sociodemographic data associated with cCMV and demonstrates that mothers of infected neonates belong to 2 markedly different sociodemographic groups in the 2 types of maternal infection. Although maternal age below 25 was a risk factor for both types of infection, the risk to deliver an infected infant following primary infection was higher in parous women born in high-resource country. Higher income was also associated with the birth of an infected infant after primary infection. The risk to deliver an infant infected following nonprimary infection was higher in unemployed women, who also belonged to low socioeconomical groups, whereas to be parous was not a risk factor. Altogether, these results suggest that the source of contamination for primary infection is mainly the mother's older child or children. However, women with lower socioeconomic status have a higher likelihood of being exposed to individuals shedding CMV in addition to their own children and therefore have a higher risk of reinfection. Because this study showed that seronegative, parous women represent the highest risk group of congenital CMV infection, we advocate that these women should be identified by CMV testing before pregnancy and targeted by prevention messages. Indeed, educational and hygiene measures aiming to avoid intimate contacts with young children are efficient to prevent primary maternal infection [29] . The strengths of our study are the large number of neonates screened representing over 84% of all births together with the concomitant availability of sociodemographic, obstetrical, and serological data in pregnant women. Its limitations are that some sociodemographic data were known for only 50% of the population and that maternal serology in the first trimester was only known in a subpopulation, though representative of the whole population at the same center
In conclusion, our results convey 2 important messages: professionals (pediatricians, pathologists…) should be aware of the low PPV of CMV PCR in saliva samples, which mandates that positive screening tests should be repeated. The burden of congenital infection is equally attributable to primary and nonprimary infections in a population with a 61% seroprevalence. However, women seronegative before pregnancy have a 4-fold higher risk to deliver an infected baby. Prevention strategies should aim at protecting all at-risk women and at particularly targeting multiparous seronegative women.
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